216 related articles for article (PubMed ID: 9865677)
1. Perspective on allogeneic melanoma lysates in active specific immunotherapy.
Mitchell MS
Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677
[TBL] [Abstract][Full Text] [Related]
2. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
Mitchell MS; Jakowatz J; Harel W; Dean G; Stevenson L; Boswell WD; Groshen S
J Clin Oncol; 1994 Feb; 12(2):402-11. PubMed ID: 8113848
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
[TBL] [Abstract][Full Text] [Related]
5. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
6. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
8. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines, a critical review--Part I.
Mitchell MS
Curr Opin Investig Drugs; 2002 Jan; 3(1):140-9. PubMed ID: 12054065
[TBL] [Abstract][Full Text] [Related]
10. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa.
Mitchell MS; Darrah D; Stevenson L
Cancer Invest; 2002; 20(5-6):759-68. PubMed ID: 12197233
[No Abstract] [Full Text] [Related]
11. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.
Elliott GT; McLeod RA; Perez J; Von Eschen KB
Semin Surg Oncol; 1993; 9(3):264-72. PubMed ID: 8516615
[TBL] [Abstract][Full Text] [Related]
12. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
Kirkwood JM
Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
[TBL] [Abstract][Full Text] [Related]
13. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
14. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
15. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
18. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
19. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of melanoma.
Mitchell MS
J Investig Dermatol Symp Proc; 1996 Apr; 1(2):215-8. PubMed ID: 9627719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]